Compare DOUG & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOUG | GBIO |
|---|---|---|
| Founded | 1911 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 35.4M |
| IPO Year | N/A | 2020 |
| Metric | DOUG | GBIO |
|---|---|---|
| Price | $2.52 | $5.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.88 |
| AVG Volume (30 Days) | ★ 300.1K | 46.6K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,030,928,000.00 | $15,270,000.00 |
| Revenue This Year | $17.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.67 | N/A |
| 52 Week Low | $1.48 | $3.00 |
| 52 Week High | $3.20 | $12.50 |
| Indicator | DOUG | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 50.70 |
| Support Level | $2.66 | $5.20 |
| Resistance Level | $2.90 | $5.54 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 2.53 | 59.32 |
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.